Aparna A. Kamat VIEW CLINICAL PROFILE

Aparna A. Kamat, MD

Associate Professor of Clinical Obstetrics and Gynecology, Academic Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University where she served as chief resident.

She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principle investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies.

Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.

Areas Of Expertise

Minimally invasive surgery Gynecologic cancer Pelvic disease Hereditary risk assessment Gynecologic malignancy
Active Clinical Trials

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum (GOG-3026)

NCT03673124

Publications

Macrophage Activation in the Ovarian Cancer Tumor Microenvironment and Design of a Novel Immunotherapy
OConnell, C, Chau, E, Vasquez, M, VandenHeuvel, S, Kamat, AA, Raghavan , S & Godin, B 2023, , Society of Gynecologic Oncology Winter Meeting, Whistler, Canada, 2/2/23 - 2/4/23.

The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C, VandenHeuvel, S, Kamat, A, Raghavan, S & Godin, B 2022, , International journal of molecular sciences, vol. 23, no. 17, 9981. https://doi.org/10.3390/ijms23179981

Ovarian Cancer
Hanafy, AK, Morani, AC, Jensen, CT, Kamat, A, Eifel, PJ & Bhosale, PR 2022, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier, pp. 452-475. https://doi.org/10.1016/B978-0-323-69538-1.00027-6

Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (Nature Medicine, (2006), 12, 8, (939-944), 10.1038/nm1447)
Thaker, PH, Han, LY, Kamat, AA, Arevalo, JM, Takahashi, R, Lu, C, Jennings, NB, Armaiz-Pena, G, Bankson, JA, Ravoori, M, Merritt, WM, Lin, YG, Mangala, LS, Kim, TJ, Coleman, RL, Landen, CN, Li, Y, Felix, E, Sanguino, AM, Newman, RA, Lloyd, M, Gershenson, DM, Kundra, V, Lopez-Berestein, G, Lutgendorf, SK, Cole, SW & Sood, AK 2021, , Nature Medicine, vol. 27, no. 12, pp. 2246. https://doi.org/10.1038/s41591-021-01566-5

Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer
Kamat, AA, Fletcher, M, Gruman, LM, Mueller, P, Lopez, A, Landen, CN, Han, L, Gershenson, DM & Sood, AK 2021, , Clinical Cancer Research, vol. 27, no. 15, pp. 4455. https://doi.org/10.1158/1078-0432.CCR-21-2121

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
TRINOVA-3/ENGOT-ov2/GOG-3001 investigators 2019, , The Lancet Oncology, vol. 20, no. 6, pp. 862-876. https://doi.org/10.1016/S1470-2045(19)30178-0

Erratum: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy (Clin Cancer Res (2019) 12(4916–4924)Doi:10.1158/1078-0432.CCR-06-0021)
Halder, J, Kamat, AA, Landen, CN, Han, LY, Lutgendorf, SK, Lin, YG, Merritt, WM, Jennings, NB, Chavez-Reyes, A, Coleman, RL, Gershenson, DM, Schmandt, R, Cole, SW, Lopez-Berestein, G & Sood, AK 2019, , Clinical Cancer Research, vol. 25, no. 10, pp. 3194. https://doi.org/10.1158/1078-0432.CCR-19-1132

Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, YA, Kamat, AA, Zhou, H, Mody, DR, Schwartz, MR, Hobday, C & Ge, Y 2015, , Cancer cytopathology, vol. 123, no. 7, pp. 435-442. https://doi.org/10.1002/cncy.21549

Ovarian Cancer Epidemiology
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach Expert Consult. Elsevier, pp. 455-478. https://doi.org/10.1016/B978-1-4377-2232-1.00026-7

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, JP, Calcagno, AM, Varma, S, Davidson, B, Elstrand, MB, Ganapathi, R, Kamat, AA, Sood, AK, Ambudkar, SV, Seiden, MV, Rueda, BR & Gottesman, MM 2012, , Clinical Cancer Research, vol. 18, no. 11, pp. 3197-3206. https://doi.org/10.1158/1078-0432.CCR-12-0056

Ovarian cancer
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, pp. 455-478. https://doi.org/10.1016/B978-1-4377-2232-1.00026-7

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Coleman, RL, Duska, LR, Ramirez, PT, Heymach, JV, Kamat, AA, Modesitt, SC, Schmeler, KM, Iyer, RB, Garcia, ME, Miller, DL, Jackson, EF, Ng, CS, Kundra, V, Jaffe, R & Sood, AK 2011, , The Lancet Oncology, vol. 12, no. 12, pp. 1109-1117. https://doi.org/10.1016/S1470-2045(11)70244-3

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
Liggett, TE, Melnikov, A, Yi, Q, Replogle, C, Hu, W, Rotmensch, J, Kamat, A, Sood, AK & Levenson, V 2011, , Gynecologic oncology, vol. 120, no. 1, pp. 113-120. https://doi.org/10.1016/j.ygyno.2010.09.019

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
Merritt, WM, Kamat, AA, Hwang, JY, Bottsford-Miller, J, Lu, C, Lin, YG, Coffey, D, Spannuth, W, Nugent, E, Han, LY, Landen, CN, Nick, AM, Stone, RL, Coffman, KT, Bruckheimer, E, Broaddus, R, Gershenson, DM, Coleman, RL & Sood, AK 2010, , Cancer Biology and Therapy, vol. 10, no. 12, pp. 1306-1314. https://doi.org/10.4161/cbt.10.12.13582

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, AK, Armaiz-Pena, GN, Halder, J, Nick, AM, Stone, RL, Hu, W, Carroll, AR, Spannuth, WA, Deavers, MT, Allen, JK, Han, LY, Kamat, AA, Shahzad, MMK, McIntyre, BW, Diaz-Montero, CM, Jennings, NB, Lin, YG, Merritt, WM, DeGeest, K, Vivas-Mejia, PE, Lopez-Berestein, G, Schaller, MD, Cole, SW & Lutgendorf, SK 2010, , Journal of Clinical Investigation, vol. 120, no. 5, pp. 1515-1523. https://doi.org/10.1172/JCI40802

Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker
Kamat, AA, Baldwin, M, Urbauer, D, Dang, D, Han, LY, Godwin, A, Karlan, BY, Simpson, JL, Gershenson, DM, Coleman, RL, Bischoff, FZ & Sood, AK 2010, , Cancer, vol. 116, no. 8, pp. 1918-1925. https://doi.org/10.1002/cncr.24997

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
Merritt, WM, Nick, AM, Carroll, AR, Lu, C, Matsuo, K, Dumble, M, Jennings, N, Zhang, S, Lin, YG, Spannuth, WA, Kamat, AA, Stone, RL, Shahzad, MMK, Coleman, RL, Kumar, R & Sood, AK 2010, , Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 985-995. https://doi.org/10.1158/1535-7163.MCT-09-0967

Frequent downregulation of miR-34 family in human ovarian cancers
Corney, DC, Hwang, CI, Matoso, A, Vogt, M, Flesken-Nikitin, A, Godwin, AK, Kamat, AA, Sood, AK, Ellenson, LH, Hermeking, H & Nikitin, AY 2010, , Clinical Cancer Research, vol. 16, no. 4, pp. 1119-1128. https://doi.org/10.1158/1078-0432.CCR-09-2642

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
Merritt, WM, Danes, CG, Shahzad, MMK, Lin, YG, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Mangala, LS, Stone, RL, Hye, SK, Gershenson, DM, Jaffe, RB, Coleman, RL, Chandra, J & Sood, AK 2009, , Cancer Biology and Therapy, vol. 8, no. 16, pp. 1596-1603. https://doi.org/10.4161/cbt.8.16.9004

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer
Kamat, AA, Coffey, D, Merritt, WM, Nugent, E, Urbauer, D, Lin, YG, Edwards, C, Broaddus, R, Coleman, RL & Sood, AK 2009, , Cancer, vol. 115, no. 12, pp. 2684-2692. https://doi.org/10.1002/cncr.24335

VIEW FULL PUBLICATIONS